VivoSeq
Oncology

Advanced Colorectal Cancer

3

Pipeline Programs↗

5

Active Trials↗

2

Companies Involved↗

Advanced Colorectal Cancer is an early-stage landscape with 3 programs across 2 companies. The most active players are Innovent Biologics (Suzhou) Co. Ltd., Suzhou Suncadia Biopharmaceuticals Co., Ltd..

Intelligence

Pipeline Metrics

Competitive Density

28/100

Pipeline Velocity

22/100

Mech. Concentration

100/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Innovent Biologics (Suzhou) Co. Ltd. logo

Innovent Biologics (Suzhou) Co. Ltd.

1 program

Phase 2Suzhou Suncadia Biopharmaceuticals Co., Ltd. logo

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

2 programs

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

67%

Monoclonal antibody

2 of 3 classified programs — the dominant modality here.

33%ALL OTHERSSmall molecule133%

Monoclonal antibody leads; the ring shows all 3 classified programs, each share of the total. Modality classified for 33% of 9 pipeline programs.

Analysis

Trial Status

5

clinical trials

Recruiting2 · 40%
Not yet recruiting2 · 40%
Enrolling by invitation1 · 20%

Clinical Trials

Trial Activity

Clinical Study of Second-Line Standard Therapy Combined With Ongericimab and Toripalimab in Patients With MSS/pMMR Colorectal Cancer Following First-Line Treatment Failure
Recruiting·SShanghai Pudong Hospital·Phase 2·NCT07106034·32 enrolled
A Phase I/II Clinical Trial Evaluating the Efficacy of Capecitabine Plus Lenvatinib in Patients With Advanced Colorectal Cancer Refractory to Irinotecan, Oxaliplatin, and Fluoropyrimidine
Enrolling by invitation·SSeoul National University Bundang Hospital·Preclinical·NCT07683949·93 enrolled
A Randomized, Open-label, Controlled, Multicenter Phase III Clinical Study of SHR-A1811 in Combination With mFOLFOX6 (-1) and Bevacizumab Versus mFOLFOX6 in Combination With Bevacizumab as First-line Treatment for Advanced Colorectal Cancer.
Not yet recruiting·Suzhou Suncadia Biopharmaceuticals Co., Ltd. logoSuzhou Suncadia Biopharmaceuticals Co., Ltd.·Phase 3·NCT07676162·300 enrolled
A Clinical Trial Evaluating the Safety, Tolerability, and Preliminary Antitumor Activity of MSH2-/- Tumor Cell Vaccines in Patients With Advanced pMMR Colorectal Cancer.
Recruiting·WWest China Hospital·Phase 1·NCT07510308·9 enrolled
A Single-Arm, Open-Label, Exploratory Phase II Clinical Trial of Sintilimab Plus Gossypol Acetate in Patients With Advanced pMMR/MSS Colorectal Cancer After Failure of at Least Two Prior Lines of Therapy
Not yet recruiting·PPeking University People's Hospital·Phase 2·NCT07656766·32 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)